Notice to Contributors

Manuscripts should be sent in triplicate (original plus two copies) to the Editor, Dr. Michael Moore. The criteria for acceptance of manuscripts to be published in the British Journal of Cancer are originality and high scientific quality. Manuscripts are accepted on the understanding that they report unpublished work that is not under consideration for publication elsewhere, that all named authors have agreed to its submission and that if accepted it will not be published in the same form, in any language, without the consent of the Publishers. Papers should be in English. Authors whose mother-tongue is not English are urgently requested to have their manuscripts checked for linguistic correctness before submission.

Manuscripts should be typewritten, double-spaced with a wide margin and on one side of the paper only. They should be accompanied by a title page numbered as 1, bearing title, authors full names, affiliation and addresses; and a summary of not more than 200 words. The author to whom correspondence, proofs and reprint requests are to be sent should be clearly indicated.

Full papers should be divided into sections:
1. Introduction
2. Materials and methods
3. Results
4. Discussion
5. Acknowledgements and References.

Short Communications (~1500 words) should not have the above section headings nor a summary.

The Editor reserves the right to make literary corrections.

Titles. These are the most read part of papers. Authors should compose them with great care. They should combine brevity with clarity; the shorter the better, not exceeding 100 letters. Authors should submit their own running title, which must not exceed 50 letters. The top of each page should carry the running title and the name of the first author.

Illustrations should be referred to in the text as "Figures" and be given Arabic numbers. They should be marked on the back with the authors name(s) and the title of the paper. Where there is any possible doubt as to the orientation of an illustration, the top should be indicated by an arrow. Photographs and photomicrographs should be high-quality unmounted glossy prints and should not be retouched. Magnification is best indicated by a line representing a defined length, included within the photograph. Colour illustrations will be accepted when found necessary by the Editor, although the author will be expected to contribute to the cost. Diagrams should be on separate sheets; they must be drawn with black Indian ink on white paper or feint-ruled graph paper and should be about twice the size of the final reproduction. Lines should be of sufficient thickness to stand reduction. Photocopies are unacceptable. Each illustration should be clearly described by a legend; all legends should be grouped on a separate sheet of paper. Lettering on figures should be minimal and should not duplicate the legend.

There should be as few Tables as possible; they should have a title and include only essential data; they should be typewritten on separate sheets and given Roman numbers.

References. Only papers closely related to the author's work should be quoted, and these should be to original papers only. Exhaustive lists should be avoided. References in the text should be made by giving the author's surname, with the year of publication in brackets. When the reference is to a specific part of a book, the page number should also be cited. When reference is made to a work by 3 or more authors, the first name followed by et al. should be used on all occasions. If several papers by the same first author and from the same year are cited, a, b, c, etc. should be added after the year of publication. It is the author's responsibility to check the accuracy of all references before submitting a manuscript. References should be brought together at the end of the paper in alphabetical order, where titles of papers and all authors' names should be given in full (except if there are more than 6 authors, when the first 3 names should be followed by "and x others", x being the actual number). Names of journals should be abbreviated as in the Index Medicus, but with full stops after abbreviations (and after authors' initials), followed by the volume number and the page number, e.g.:


References to books and monographs should appear as in the following examples:


Abbreviations and units should follow the standards laid down in Units, Symbols and Abbreviations published by the Royal Society of Medicine (third edition, 1977).

Offprints may be ordered on the form accompanying proofs; 25 will be supplied free of charge.

*Editorial correspondence should be addressed to the Editor, Dr Michael Moore, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX.

*Citation of Conference Proceeding or Meetings Abstracts should be avoided unless there is no other reference.
The British Journal of Cancer

EDITORIAL BOARD

D. G. Harnden Chairman
M. Moore Editor

G. E. D. Adams
M. R. Alderson
P. Alexander
K. D. Bagshawe
R. J. Berry
G. D. Birnie
N. M. Bleehen
P. Brookes
R. L. Carter
T. A. Connors

E. H. Cooper
D. Crowther
A. R. Currie
M. J. Embleton
J. F. Fowler
B. W. Fox
P. Gallimore
J. S. Jenkins
N. H. Kemp
B. Ketterer

L. J. Kinlen
J. Knowelden
N. A. Mitchison
A. M. Neville
R. Peto
B. R. Rabin
G. G. Steel
N. G. Testa
M. P. Vessey
R. A. Weiss

MACMILLAN PRESS LTD
Aims and Scope

The British Journal of Cancer will accept papers which contain new information, constitute a distinct contribution to knowledge, and are relevant to the clinical, epidemiological, pathological or molecular aspects of oncology.

The Journal is published monthly on behalf of the Cancer Research Campaign by the Scientific and Medical Division, The Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS. Telephone: Basingstoke (0256) 29242.

ISSN 0007-0920

Manuscripts plus two copies and all editorial correspondence should be sent to the Editor: Dr. Michael Moore, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX.

Annual subscription: UK £92; USA & Canada $225; Rest of World £113, Airmail £138; (or equivalent in any other currency). Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Journals Ltd. and sent to Subscription Department, Brunel Road, Basingstoke, Hampshire, RG21 2XS. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment.

Second class postage permit applied for.

Enquiries concerning advertising space or rates should be addressed to: Advertising Department, British Journal of Cancer, 4 Little Essex Street, London WC2R 3LF. Telephone: 01-836 6633.

Copyright © 1983 by Cancer Research Campaign.

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by The Macmillan Press Ltd for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $01.00 per copy, plus 0.10 per page is paid directly to CCC, 21 Congress St., Salem, MA 01970, USA.

0007-0920/83 $1.00 + 0.10

Printed in Great Britain by Bell and Bain Ltd., Glasgow.


SHAU, H., KOREN, H.S. & DAWSON, J.R. Human natural killing against ovarian carcinoma.


STUART, A.E. The production of abnormal cells and Reed-Sternberg-like cells from normal lymphocytes.


WILLIAMS, E.D., WAREHAM, K.A. & HOWELL, S. Direct evidence for the single cell origin of mouse liver cell tumours.

**Contents**

**Human Cancer**

BAUER, G. Induction of Epstein-Barr virus early antigens by corticosteroids: Inhibition by TPA and retinoic acid.

BURRICHTER, H., HEIT, W., SCHAADT, M., KIRCHNER, H. & DIEHL, V. Production of colony stimulating factors by Hodgkin cell lines.

STICH, H.F. & ROSIN, M.P. Quantitating the synergistic effect of smoking and alcohol consumption with the micronucleus test on human buccal mucosa cells.


GOYA, R.G. & SOSA, Y.E. Changes in chromatin composition associated to hormone-dependent mammary tumor regression.

PAULIE, S., HANSSON, Y., LUNDBLAD, M.-L. & PERLMANN, P. Lectins as probes for identification of tumor associated antigens on urothelial and colonic carcinoma cell lines.


**Experimental Cancer**

HEARD, J.M., FICHELSON, S., CHOPPIN, J. & VARET, B. Autocrine function of murine F-MuLV induced myeloblastic cell lines.


RICCARDI, C., ALLAVENA, P., ORTALDO, J. & HERBERMAN, R.B. Cloned lines of SJL/J spleen cells with cytotoxic reactivity.

ROTTER, V., ABUTBUL, H. & WOLF, D. The presence of p53 transformation-related protein in Ab-MuLV transformed cells is required for their development into lethal tumors in mice.


GAZIT, A., YANIV, A., ILANI, A., IANCONESCU, M., PERK, K. & ZIMBER, A. Genetic control of the organ specificity of lymphoproliferative disease virus (LPDV) of turkeys.


SCHAFFAR-DESHAYES, L., CHOPPIN, J. & LEVY, J.P. Detection of H-2D<sup>δ</sup> and H-2K<sup>δ</sup> molecules in purified Rauscher leukaemia virus.

BRUNDA, M.J., WILTROUT, R.H., HOLDEN, H.T. & VARESIO, L. Selective inhibition by monosaccharides of tumor cell cytotoxicity mediated by mouse macrophages, macrophage-like cell lines, and natural killer cells.

BRULEY-ROSSET, M. & RAPPAORT, H. Natural killer cell activity and spontaneous development of lymphoma. Effects of single and multiple injections of interferon into young and aged C57BL/6 mice.
Constructive therapy in destructive diseases

Deca-Durabolin as an adjunct to chemotherapy or radiotherapy

Deca-Durabolin protects against bone marrow depression

Deca-Durabolin improves the patient's sense of well-being

Deca-Durabolin when a prolonged anti-catabolic effect is needed

Prescribing information

Uses: All conditions requiring a powerful and prolonged anabolic or anti-catabolic stimulus, and as an adjunct to specific anti-anemic therapy. Deca-Durabolin should be administered only by deep injection into the gluteus maximus muscle. Adults: 25-50mg every three weeks. Children: Up to 0.4mg/kg every three weeks. In the aneamias associated with chronic renal failure and in malignant disease treated with adjuvant therapy. Adults: 100-200mg weekly. Children: 0.75-1.5mg/kg weekly. Contra-indications: Pregnancy, carcinoma of prostate or testes, and mammary carcinoma in the male. Precautions: Discontinue therapy if hypercalcaemia or hypercalciuria develop. Patients with myocardial, hepatic or renal dysfunction, migraine, epilepsy, or hypertensive or history of coronary artery disease should be observed carefully. Alterations in glucose tolerance may occur. Skeletal maturation may be accelerated in children. Deca-Durabolin is usually free from virilising properties at the recommended dose levels. Larger doses, prolonged treatment and frequent administration may cause virilisation in some sensitive women. If this occurs, discontinue therapy. Hoarseness of the voice may be the first symptom of vocal change which may lead to irreversible lowering of the voice. Amenorrhoea in women and inhibition of spermatogenesis in the male may also occur. Changes have been seen in the outcome of liver function tests, but treatment need not be interrupted. The changes appear to be reversible on cessation of therapy. Interactions: One possible case of interaction with an oral anti-coagulant has been observed, but it is advisable to check the prothrombin time. Basic NHS cost 3 x 1ml ampoules, strength 100mg/ml - £22.01. Product Licence Number 25mg/ml PL 0065/0025, 50mg/ml PL 0065/0056, 100mg/ml PL 0065/0036.


Organon Laboratories Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4BH.